Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis

被引:62
作者
Czaja, AJ
Carpenter, HA
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA
关键词
pathogenic mechanisms; plasma cells; relapse;
D O I
10.1034/j.1600-0676.2003.00810.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Relapse of type 1 autoimmune hepatitis after drug withdrawal may relate to incomplete histological improvement during corticosteroid therapy and/or persistence of pathogenic mechanisms. Aim: Determine the histological features prior to drug withdrawal that are associated with relapse in patients satisfying pre-established clinical, laboratory, and histological criteria for remission and relapsing after corticosteroid withdrawal. Methods: One hundred liver tissue samples obtained immediately prior to corticosteroid withdrawal from 88 patients who had previously satisfied criteria for histological remission were reviewed retrospectively. Results: Histological findings in the patients who relapsed were similar to those in the patients who sustained remission in regard to histological activity index (1.7 +/- 0.1 versus 1.6 +/- 0.2, P = 0.6), fibrosis score (2.6 +/- 0.3 versus 2.3 +/- 0.4, P = 0.5), and frequencies of interface hepatitis (36% versus 20%, P = 0.2), cirrhosis (21% versus 17%, P = 0.8), and normal or near normal tissue (9% versus 7%, P > 0.9). Only the presence of portal plasma cells was associated with relapse (31% versus 7%, P = 0.01). The positive predictability of portal plasma cell infiltration for relapse was 92%, but its sensitivity was only 31%. Conclusions: Portal plasma cell infiltration is predictive of relapse after drug withdrawal in tissue specimens already satisfying criteria for remission. Portal plasma cell infiltration may be indicative of an active antibody-dependent pathogenic mechanism. Its low sensitivity for relapse indicates the need for other complementary predictors of outcome.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 46 条
[1]  
Almawi WY, 2001, MOD ASP IMMUNOBIOL, V2, P78
[2]   International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[3]   CYTOKINE PROFILE OF VIRAL AND AUTOIMMUNE CHRONIC ACTIVE HEPATITIS [J].
ALWABEL, A ;
ALJANADI, M ;
RAZIUDDIN, S .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (06) :902-908
[4]   Non-Th2 regulatory T-cell control of Th1 autoimmunity [J].
Bach, JF .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 54 (1-2) :21-29
[5]   Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies [J].
Brattsand, R ;
Linden, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 :81-90
[6]  
Carpenter Herschel A, 2002, Clin Liver Dis, V6, P685, DOI 10.1016/S1089-3261(02)00022-3
[7]  
COCHRANE AMG, 1976, LANCET, V1, P441
[8]   IMMUNOCYTOCHEMICAL STUDY OF GAMMA-GLOBULIN IN LIVER IN HEPATITIS AND POSTNECROTIC-CIRRHOSIS [J].
COHEN, S ;
OHTA, G ;
SINGER, EJ ;
POPPER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1960, 111 (02) :285-+
[9]   AUTOIMMUNE HEPATITIS - EVOLVING CONCEPTS AND TREATMENT STRATEGIES [J].
CZAJA, AJ .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) :435-456
[10]   Drug therapy in the management of type 1 autoimmune hepatitis [J].
Czaja, AJ .
DRUGS, 1999, 57 (01) :49-68